Creatinine Artifact — Creatine Supplementation

What this model detects

Creatine monohydrate supplementation causes a pharmacokinetic artifact that mimics kidney dysfunction on standard clinical chemistry: serum creatinine rises 15–30% above pre-supplementation baseline, while true glomerular filtration rate is unchanged.

This artifact affects:

• Serum creatinine (direct measurement)
• Creatinine-based eGFR (all standard equations: CKD-EPI, MDRD, Cockcroft-Gault)
• BUN:creatinine ratio (shifts artifactually)
• Urine creatinine (elevated excretion rate)
• Apple Watch estimated GFR (uses creatinine-based equations)

What features mislead

Feature	Direction of artifact	Magnitude	Reliability
Serum creatinine	↑ 15–30%	Dose/duration dependent	High — well-characterized
Creatinine-based eGFR	↓ artifactually (10–30 mL/min)	Variable	High — direct consequence
Apple Watch eGFR	↓ artifactually	Same magnitude	High — same equation
Cystatin C	Unchanged	None	High — not affected by creatine
BUN	No meaningful change	Minimal	High
True GFR (iohexol/51Cr-EDTA)	Unchanged	None	Gold standard

Body composition artifacts during loading:

• BIA impedance: Falsely lower body fat %, falsely higher lean mass — ICW shifts increase conductive mass
• DEXA: Falsely higher lean mass — water registered as lean tissue
• Scale weight: +0.5–2.0 kg during loading (water), +0.5–1 kg long-term (sustained ICW)

Certainty limits

High certainty:

• Creatinine rises are a direct pharmacokinetic consequence of creatine → creatinine conversion (~1–2% of total body creatine pool per day)
• True GFR is unaffected in healthy adults
• Cystatin C is not affected by creatine supplementation
• The artifact is fully reversible upon cessation (creatinine normalizes within ~7–14 days of stopping)

Moderate certainty:

• The artifact magnitude scales roughly with dose (loading > maintenance) but individual variation is substantial
• Body composition BIA/DEXA artifacts during loading are well-characterized qualitatively; precise magnitude varies

Low certainty:

• Non-responders (~20–30% of users) may show minimal creatinine elevation — absence of artifact does not rule out creatine use

Route / dose / timing caveats

• Loading phase (20 g/day × 5–7 days): Artifact is largest — expect near-maximum creatinine elevation
• Maintenance phase (3–5 g/day): Artifact is smaller but persistent and dose-proportional — eGFR still confounded at steady state
• Timing after cessation: Creatinine normalizes within 7–14 days of stopping; eGFR interpretation should wait ≥14 days post-cessation for clinical decisions
• Hydration status: Dehydration elevates serum creatinine independently — compounding with creatine artifact can produce clinically misleading values
• Age 65+: The artifact is the same magnitude but absolute eGFR values are already lower; the artifact can push apparent eGFR across clinical thresholds

What to use instead

For kidney function monitoring in creatine users:

1. Cystatin C-based eGFR — not confounded by muscle mass, diet, or creatine. Requires clinical blood draw (not available on consumer wearables).
2. Measured GFR (iohexol or 51Cr-EDTA clearance) — gold standard research method; not clinically practical.
3. Apple Watch eGFR is not usable during creatine supplementation. Flag and suppress any kidney function alerts from wearable-derived eGFR.

Practical Vitals protocol:

WHILE user is on creatine supplementation:
  SUPPRESS: Apple Watch eGFR alerts
  SUPPRESS: serum creatinine trending as kidney concern
  REQUEST: cystatin C-based eGFR on next blood panel
  NOTE: Body composition BIA/DEXA confounded for 4–6 weeks post-initiation
  CADENCE: re-evaluate cystatin C every 6 months or per standard wellness

Relationship to this vault

• Creatine — the parent substance note (hub); this detection model is a satellite
• Sarcopenia Detection — links to this detection model as a kidney monitoring caveat for muscle health panels
• Muscle Health Biomarkers — mentions cystatin C as the preferred kidney marker; this note provides the mechanistic basis